Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study

Ebina, K.; Noguchi, T.; Hirao, M.; Hashimoto, J.; Kaneshiro, S.; Yukioka, M.; Yoshikawa, H.

doi:https://doi.org/10.1007/s00198-015-3369-6

Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study

Ebina, K.; Noguchi, T.; Hirao, M. et al.

Osteoporosis International, 2016, 27(1), 351-359

Number of Access:814（2025-09-03 11:38 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/93258

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
OsteoporosisInt_27_1_351	pdf	None	945 KB	39	2023.12.07

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
Creator	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 CreatorName Ebina, K.
	NRID 1000050812294 1000050812294 researchmap permalink takaakinoguchi takaakinoguchi ORCID 0000-0001-9938-6780 0000-0001-9938-6780 CreatorName Noguchi, T.
	NRID 1000010527708 1000010527708 CreatorName Hirao, M.
	NRID 1000040237938 1000040237938 CreatorName Hashimoto, J.
	CreatorName Kaneshiro, S.
	CreatorName Yukioka, M.
	NRID 1000060191558 1000060191558 CreatorName Yoshikawa, H.
Subject	Alendronate
	Minodronate
	Osteoporosis
	Rheumatoid arthritis
	Risedronate
Description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-015-3369-6
Description	Ebina K., Noguchi T., Hirao M., et al. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporosis International 27, 351 (2016); https://doi.org/10.1007/s00198-015-3369-6.
Abstract	Summary: Switching weekly ALN or RIS to monthly MIN in patients with RA, of whom two-thirds were treated with low-dose PSL, significantly decreased bone turnover markers and increased BMD at 12 months, suggesting that monthly MIN may be an effective alternative treatment option of oral bisphosphonate treatment. Introduction: The aim of this prospective, observational study was to evaluate the effects of switching weekly alendronate (ALN 35 mg) or risedronate (RIS 17.5 mg) to monthly minodronate (MIN 50 mg) in patients with rheumatoid arthritis (RA). Methods: Patient characteristics were as follows: n = 172; 155 postmenopausal women, age 65.5 (44–87) years; T-score of lumbar spine (LS), −1.4; total hip (TH), −1.8; femoral neck (FN), −2.1; dose and rate of oral prednisolone (2.3 mg/day), 69.1 %; prior duration of ALN or RIS, 46.6 months; were allocated, based on their preference, to either the (1) continue group (n = 88), (2) switch-from-ALN group (n = 44), or (3) switch-from-RIS group (n = 40). Results: After 12 months, increase in BMD was significantly greater in group 3 compared to group 1: LS (4.1 vs 1.2 %; P < 0.001), TH (1.9 vs −0.7 %; P < 0.01), and FN (2.7 vs −0.5 %; P < 0.05); and in group 2 compared to group 1: LS (3.2 vs 1.2 %; P < 0.05) and TH (1.5 vs −0.7 %; P < 0.01). The decrease in bone turnover markers was significantly greater in group 3 compared to group 1: TRACP-5b (−37.3 vs 2.5 %; P < 0.001), PINP (−24.7 vs −6.2 %; P < 0.05), and ucOC (−39.2 vs 13.0 %; P < 0.05); and in group 2 compared to group 1: TRACP-5b (−12.5 vs 2.5 %; P < 0.05) at 12 months. Conclusions: Switching weekly ALN or RIS to monthly MIN in patients with RA may be an effective alternative treatment option of oral bisphosphonate treatment.
Publisher	Springer Nature
Source Title	Osteoporosis International
Volume (Issue)	27(1)
Page	351-359
Date of Issued	2016-01-01
Language	English
Handle URL	https://hdl.handle.net/11094/93258
PISSN	0937941X
eISSN	14332965
Relation.isVersionOf	DOI (Publisher Version) https://doi.org/10.1007/s00198-015-3369-6
Access Rights	open access
oaire:version	Accepted Manuscript
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Osteoporosis International. 2016, 27(1), p. 351-359
DC.title	Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
DC.creator	Ebina, K.
	Noguchi, T.
	Hirao, M.
	Hashimoto, J.
	Kaneshiro, S.
	Yukioka, M.
	Yoshikawa, H.
DC.publisher	Springer Nature
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2016-01-01
DC.identifier	https://doi.org/10.1007/s00198-015-3369-6
DC.subject	Alendronate
	Minodronate
	Osteoporosis
	Rheumatoid arthritis
	Risedronate
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s00198-015-3369-6
DC.description	Ebina K., Noguchi T., Hirao M., et al. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study. Osteoporosis International 27, 351 (2016); https://doi.org/10.1007/s00198-015-3369-6.
DCTERMS.abstract	Summary: Switching weekly ALN or RIS to monthly MIN in patients with RA, of whom two-thirds were treated with low-dose PSL, significantly decreased bone turnover markers and increased BMD at 12 months, suggesting that monthly MIN may be an effective alternative treatment option of oral bisphosphonate treatment. Introduction: The aim of this prospective, observational study was to evaluate the effects of switching weekly alendronate (ALN 35 mg) or risedronate (RIS 17.5 mg) to monthly minodronate (MIN 50 mg) in patients with rheumatoid arthritis (RA). Methods: Patient characteristics were as follows: n = 172; 155 postmenopausal women, age 65.5 (44–87) years; T-score of lumbar spine (LS), −1.4; total hip (TH), −1.8; femoral neck (FN), −2.1; dose and rate of oral prednisolone (2.3 mg/day), 69.1 %; prior duration of ALN or RIS, 46.6 months; were allocated, based on their preference, to either the (1) continue group (n = 88), (2) switch-from-ALN group (n = 44), or (3) switch-from-RIS group (n = 40). Results: After 12 months, increase in BMD was significantly greater in group 3 compared to group 1: LS (4.1 vs 1.2 %; P < 0.001), TH (1.9 vs −0.7 %; P < 0.01), and FN (2.7 vs −0.5 %; P < 0.05); and in group 2 compared to group 1: LS (3.2 vs 1.2 %; P < 0.05) and TH (1.5 vs −0.7 %; P < 0.01). The decrease in bone turnover markers was significantly greater in group 3 compared to group 1: TRACP-5b (−37.3 vs 2.5 %; P < 0.001), PINP (−24.7 vs −6.2 %; P < 0.05), and ucOC (−39.2 vs 13.0 %; P < 0.05); and in group 2 compared to group 1: TRACP-5b (−12.5 vs 2.5 %; P < 0.05) at 12 months. Conclusions: Switching weekly ALN or RIS to monthly MIN in patients with RA may be an effective alternative treatment option of oral bisphosphonate treatment.
DC.format	93258
citation_title	Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study
citation_author	Ebina, K.
	Noguchi, T.
	Hirao, M.
	Hashimoto, J.
	Kaneshiro, S.
	Yukioka, M.
	Yoshikawa, H.
citation_publisher	Springer Nature
citation_language	English
citation_date	2016-01-01
citation_journal_title	Osteoporosis International
citation_volume	27
citation_issue	1
citation_firstpage	351
citation_lastpage	359
citation_doi	https://doi.org/10.1007/s00198-015-3369-6
citation_public_url	https://hdl.handle.net/11094/93258

Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rheumatoid arthritis: a 12-month prospective study

Link to primary information

Item Information

Show details